Braces, Inc.: The 5 Companies Buying Up America’s Orthodontists

One is worth $2.4 billion and is closing in on 600 offices. Another added 37 practices in a single day, without a dollar of Wall Street money. A $9 billion darling that tried to skip the orthodontist entirely went bankrupt and stranded its customers. And the pioneer that invented the whole playbook ended in bankruptcy and an SEC fraud case. Here is who really owns the smile business, by the numbers, and why a backlash is building.

Here is a question almost no patient asks before getting braces: who owns the office?

For most of the last century the answer was boring and reassuring. Your orthodontist owned your orthodontist. One doctor, one shingle, one waiting room with a fish tank. You picked them, they treated you, the end.

That world is disappearing. Over the past decade a tidal wave of capital has crashed into orthodontics and started buying practices by the hundred. The buyers are called orthodontic support organizations, or OSOs, and the pitch to the doctor is irresistible: keep treating patients, hand us the paperwork, the payroll, the marketing, and the real estate headaches, and take a big check while you are at it.

The result is an industry consolidating in slow motion. The share of U.S. dentists tied to a support organization jumped from 8.8 percent in 2017 to 13 percent by 2022, and it runs far higher among younger doctors, according to the American Dental Association’s Health Policy Institute. Orthodontics, with its predictable treatment plans and cash-pay economics, has been one of the juiciest targets of all.

So we did the reporting. We pulled press releases, private-equity announcements, Becker’s DSO lists, court records, and company histories to rank the five largest orthodontic support organizations in America, chart how fast they got there, and lay out the growing backlash. Fair warning: it gets weird, and a little dark.

First, the scoreboard

The single most important fact about this ranking is the gap at the top. This is not a close race. Number one is bigger than numbers two through five combined, and it is not particularly close.

The growth machine: how you buy 500 orthodontists

Before we meet the players, understand the game they are playing. It is called a roll-up, and private equity has run this exact play in veterinary clinics, dermatology, eye care, and now teeth.

The recipe is simple. Find a market that is huge, fragmented, and boring. Orthodontics qualifies on all three: there are roughly 10,400 orthodontists in the country, most of them running one or two offices, in a specialty nobody writes magazine covers about. Buy a strong “platform” practice. Then use it to buy the neighbors, one after another, paying for each with a mix of cash and equity. Each acquisition makes the whole thing bigger, and bigger companies get valued at richer multiples. Buy at five times earnings, bolt it onto a platform worth twelve times earnings, and you have created value out of thin air. Financiers call this “multiple arbitrage.” Everyone else calls it getting rich by shopping.

The fuel is debt, and lots of it. The pace can be breathtaking. And the growth curves, when you plot them, look less like a business and more like a rocket launch.

Now let us meet the companies actually running the play, from biggest to smallest.

1. Smile Doctors

Start with the giant, because everything else in this industry is measured against it.

Ten years ago, Smile Doctors did not exist. Today it runs close to 600 orthodontic offices across 36 states, employs more than a thousand people, and was valued at roughly $2.4 billion when Thomas H. Lee Partners bought in alongside Linden Capital Partners in early 2022. Independent estimates put its annual revenue north of half a billion dollars. If orthodontics has a Starbucks, this is it.

The origin story is smaller and more human than the balance sheet. A Florida orthodontist named Dr. Scott Law moved his wife and five kids to central Texas and built a practice around an almost corny philosophy he still repeats: love on patients first, and put braces on them second. Games in the waiting room. Massage chairs. In 2015, that single successful office became the seed for a roll-up.

Then came the money, in three waves. Sheridan Capital seeded the roll-up in 2015. Linden Capital took majority control in 2017, when the company had about 90 offices. And in January 2022, Thomas H. Lee Partners bought in as an equal partner at that $2.4 billion mark, by which point the business had quadrupled. Watch what a decade of that looks like.

What makes Smile Doctors more interesting than a standard buyout is that it did not slam on the brakes when dental financing got tight in 2023 through 2025. It kept buying while rivals froze, swallowing the 70-office myOrthos in one gulp. It also lets affiliated doctors keep equity, so the orthodontists have skin in the game rather than a gold watch and a non-compete.

“Love on patients first, and put braces on them second.”Dr. Scott Law, co-founder of Smile Doctors

2. PepperPointe Partnerships

Now the plot twist. The second-largest player in this business took exactly zero dollars of private-equity money, and its founder will tell you that was the entire point.

Dr. Greg White, a Kentucky orthodontist, watched private equity march into dentistry and did not like the ending. Sell your practice to a fund, the logic goes, and the fund needs an exit in three to five years, which means selling you again to a bigger fund, which means someone, eventually, has to squeeze the practice to make the math work. His line about it has become an industry catchphrase.

“I didn’t want to have to justify an exit strategy that was just negotiating the terms of my surrender.”Dr. Greg White, founder of PepperPointe Partnerships

So he built the opposite: a doctor-owned cooperative. Instead of selling to a fund, the orthodontists and pediatric dentists pooled their practices and kept the equity themselves. Nobody bought anyone out. They threw all their assets in together.

The scale it reached without Wall Street is genuinely surprising: roughly 130 offices and about 150 doctors, more than 100 of them equity owner-partners. On a single day in October 2020, PepperPointe closed 37 practice transactions at once and nearly doubled overnight. Where private equity thinks in three-to-five-year exits, PepperPointe likes to say it thinks in three-to-five generations.

One honest caveat for the ranking: PepperPointe is not purely orthodontic. It began as 28 orthodontic offices plus 22 pediatric dental offices and later added general dentistry. We include it because its orthodontic roots run deep, its founder is an orthodontist, and by raw office count it is the second-largest support organization touching this specialty. Purists who want a strictly ortho-only list can slide Southern Orthodontic Partners into the two slot, and they would not be wrong.

3. Southern Orthodontic Partners

If Smile Doctors is the incumbent and PepperPointe is the rebel, Southern Orthodontic Partners is the challenger sprinting up the leaderboard.

It launched in 2019 as the first platform investment out of a new fund from Shore Capital Partners, a Chicago private-equity firm that specializes in exactly this move: find a fragmented, unglamorous healthcare niche, buy a good anchor practice, and roll up the neighbors. When a billion-dollar fund launches a new healthcare company, the plan is rarely subtle.

The growth has been ferocious. From two founding practices in 2020, Southern Orthodontic Partners reached 48 practices and 85 locations across 13 states by early 2024, then kept going, pushing past 120 locations and into roughly 20 states plus Washington, D.C. It brands itself, with Southern confidence, as “the preeminent orthodontic services provider in the South,” a claim that gets harder to argue with every quarter. In a consolidating market, the hungry challenger with a fund behind it is exactly the profile that either catches the leader or gets bought by it.

4. Bond Orthodontic Partners

Bond is the youngest company on this list, and it made a deliberate bet the others did not: go deep, not wide.

Formed in 2022 by BPOC (Beecken Petty O’Keefe), a Chicago private-equity firm that invests only in healthcare, Bond concentrated its roughly 40-plus offices across just seven Western states: Arizona, California, Idaho, Montana, Nevada, Utah, and Washington. Density over sprawl. Its model leans on joint ventures that let doctors keep clinical control while Bond handles the business machinery.

BPOC captured the whole thesis of this industry in one line: high-quality, doctor-centric orthodontic platforms with “true partnership alignment” are, in their words, rare. Translation: the practices are out there, they are just hard to roll up well, and whoever does it cleanly wins. Bond is betting it can be that clean operator in one region before it expands.

5. Orthodontic Experts

The last name on the list quietly proves you do not need a private-equity fund to build something real.

Orthodontic Experts was founded in 2013 by Dr. Yaroslav Yarmolyuk and has grown to about 34 offices across Illinois, Indiana, and Wisconsin with no outside private equity at all. It is doctor owned, ortho-focused, and regional by design. In a field where the headline numbers come from financiers, this is a reminder that plain old operating still compounds.

The detail that tells you everything: rather than fight the industry-wide shortage of trained dental assistants, Orthodontic Experts built its own school to train them. That is the kind of unglamorous, vertically-integrated problem-solving that never makes a private-equity press release but does make a durable business.

The wildcard: MB2 Dental

One more name belongs in this conversation, even though it does not fit neatly on an ortho-only leaderboard. MB2 Dental is a general dental organization, not an orthodontic specialist. But it is enormous, it is pushing into orthodontics fast, and its model is the single clearest example of the equity machine driving this entire industry.

MB2 crossed 800 affiliated practices across 45 states in 2025, with roughly 1,900 doctors, and was valued at more than $3.5 billion when Warburg Pincus put in $525 million in late 2024. Founded in 2007 by a Dallas dentist, Dr. Chris Villanueva, it bristles at the word “corporate” and insists it is not a “DSO” at all but a “Dental Partnership Organization,” in which the doctors collectively hold a large chunk of the equity. It keeps adding orthodontic and specialty practices, from Dunn Orthodontics in California to Comizio Orthodontics in New York, though it does not disclose how many of its 800 offices are ortho.

We flag MB2 not to rank it against the ortho specialists, but because it is the clearest window into how these deals actually work, and where the criticism begins. Which brings us to the part nobody prints in the recruitment brochure.

The part they don’t put in the brochure

Here is the pitch a selling orthodontist hears. We will value your practice at a big multiple, far more than you could get selling to another dentist down the street. You keep treating patients. You take a large check today, roll some equity into the parent company, and get a “second bite of the apple” when we sell the whole thing to an even bigger buyer in a few years. Everybody wins.

Now here is how the sausage is actually made.

Step one: inflate the number you multiply

A practice is priced on a multiple of its EBITDA (earnings before interest, taxes, depreciation, and amortization). But before applying that multiple, the buyer recasts the doctor’s pay. Owner-orthodontists tend to pay themselves well. The buyer strips that out and pencils in what it would cost to hire an associate to do the same clinical work, often around 28 to 32 percent of production. Because that market wage is lower than what the owner was taking home, the practice’s “adjusted” EBITDA jumps. Then the multiple gets applied to the bigger number. Buyers call this a fair, apples-to-apples normalization. Skeptics call it cutting the doctor’s pay on paper to inflate the sticker price. Both are describing the same maneuver.

Step two: most of the “price” is not cash

The headline number is dazzling. The cash is smaller. In a typical deal the doctor gets roughly 60 to 75 percent in cash at closing, with the rest in rollover equity plus an earnout tied to hitting targets. That equity is a stake in the parent holding company, and here is the catch: it usually pays nothing along the way, and you cannot turn it into cash until the next “liquidity event,” when the whole platform is sold or recapitalized, typically three to seven years out. Its worth on paper depends entirely on the multiple the next buyer pays for the whole aggregated company, a number nobody knows at signing.

Step three: pray the music keeps playing

See the dependency? A doctor’s paper equity only becomes real money if a bigger buyer shows up later and pays an even richer multiple. The model needs a continuous chain of ever-larger recapitalizations. When dentists and analysts get cynical about it, they reach for loaded metaphors. One practice-management veteran likens it to musical chairs: the music plays and everyone is having fun until it stops, and someone has quietly removed the seats. A dental-industry analysis called it a bubble built on the “greater fool” theory, the assumption that someone will always pay more. Even inside private equity, one European fund chief told PitchBook that firms selling companies to each other at ever-higher prices is “why you can talk about a Ponzi.”

The music slowed down

When interest rates spiked, the cheap debt that powers roll-ups got expensive, and the exit door narrowed. A 2025 industry survey found that more than 50 significant DSO sale processes were abandoned starting in mid-2022. Valuation multiples on large platforms compressed hard.

The people left holding the bag are the doctors. As one industry tracker put it, many who sold in recent years rolled over equity “expecting a second transaction within three to five years,” only to watch those recaps get “delayed” as the M&A market seized up. Their second bite of the apple is stuck on a tree that stopped growing.

And the smart money? It has largely moved on to the next shiny thing. By late 2025, technology had swelled to about a quarter of all private-equity deal value, with sponsors piling into software and anything that could credibly staple the letters “AI” to its pitch deck. The labor-intensive grind of actually running dental offices lost its status as the hot trade. The capital that inflated orthodontic valuations for a decade went hunting for a faster return, and a lot of it found one in a data center. That does not mean the OSOs collapse tomorrow. The biggest are healthy and still growing. But the doctors who were promised a life-changing “second bite” are learning that the promise had an expiration date nobody printed on the label.

The backlash: corporate dentistry’s reputation problem

Now the uncomfortable part, and the reason so many patients get a knot in their stomach when they learn their friendly neighborhood office is owned by a holding company three states away.

Let us be scrupulously fair first. None of the five orthodontic companies above has been accused of the abuses in this section. But they operate in a corner of healthcare whose reputation was badly bruised by others, and that history is exactly why “corporate dentistry” is a loaded phrase. To understand the suspicion the OSOs are up against, you have to know the rap sheet.

Exhibit A: the incentive problem

When a business needs to hit growth targets, the temptation to do more treatment, and to start it sooner, creeps in. This is not a conspiracy theory. It is documented. When the Justice Department settled with the dental chain Kool Smiles, it found the company “pressured dentists to meet production goals through a system of financial incentives and disciplinary actions” and “ignored complaints” of overtreatment. Kool Smiles and its manager paid $23.9 million in 2018 to resolve claims that they billed government programs for medically unnecessary procedures on children.

It was not the only one. In 2010 the operator of the Small Smiles chain paid $24 million to settle allegations it billed Medicaid for unnecessary baby root canals, crowns, and extractions on low-income kids. And a 2013 Senate investigation into the corporate practice of dentistry concluded that some chains put “profits before patient care.”

Exhibit B: the sales floor

The most vivid picture of what quota-driven dentistry can feel like came from a PBS FRONTLINE investigation into Aspen Dental, one of the country’s largest dental chains (a general DSO, not an orthodontic OSO, but the cautionary tale is the same). A former office manager described the pressure bluntly.

Regulators have kept Aspen busy. New York’s attorney general barred its management company from making patient-care decisions in 2015. Massachusetts reached a $3.5 million settlement over deceptive advertising in 2023. California settled with the company over corporate-practice-of-dentistry violations in 2026. Aspen has said it strives to make care affordable and accessible; the settlements speak for themselves.

Exhibit C: when you skip the orthodontist entirely

The purest cautionary tale in this whole story is SmileDirectClub, the mail-order aligner company that tried to cut the orthodontist out of orthodontics. Customers took their own mouth impressions at home, a remote dentist signed off, and clear aligners showed up in the mail. Wall Street loved it. The company went public in 2019 at a valuation near $8.9 billion.

Orthodontists were alarmed from the start. The American Association of Orthodontists publicly warned that moving teeth without hands-on supervision could cause irreversible damage, and filed complaints with dozens of state dental boards. The District of Columbia’s attorney general later found the company had forced unhappy customers to sign gag orders to get refunds, and freed 17,000 of them from those NDAs in 2023.

Then it all fell apart. SmileDirectClub filed for bankruptcy and abruptly shut down in December 2023, ending its “lifetime guarantee” and stranding customers mid-treatment. To add injury to injury, New York’s attorney general recovered $4.8 million in 2024 for tens of thousands of people who kept getting billed monthly after the company stopped providing any care at all. From $8.9 billion to zero, with the customers holding the bag.

Exhibit D: the doctors are nervous too

It is not only patients. Orthodontists themselves are openly uneasy about what selling to a fund does to the work. In a 2025 trade-press deep dive on private equity in orthodontics, one orthodontist called a “decrease in quality of clinical care the ultimate nightmare,” and “erosion of clinical autonomy” was the single most-cited worry among doctors weighing an offer. When a five-year earnout ties your paycheck to production, the fear goes, the treatment plan can start answering to a spreadsheet.

Regulators are circling the model itself. The Federal Trade Commission spent 2024 scrutinizing private-equity roll-ups in healthcare, and a widely cited JAMA study found that prices rose after private equity acquired medical practices. The academic and regulatory mood around this business has shifted from curiosity to suspicion.

Two models, one industry

Strip away the logos and this whole business comes down to a single fault line: who owns the equity, and what do they want from it?

* MB2 is a general dental organization with a growing orthodontic arm, shown for scale but not part of the orthodontics-only ranking.

The private-equity model chases scale with outside capital. It moves fast, buys aggressively, and eventually needs a financial exit. The doctor-owned model grows slower, keeps the equity with the people doing the treatment, and answers to no fund’s clock. Neither is automatically better. But they behave very differently, and as a patient you deserve to know which one is standing behind the chair.

What this means for you, the patient

None of this means you should flee a practice because it belongs to a group, or blindly trust one because it hangs an independent shingle. Plenty of corporate-affiliated offices deliver excellent, ethical care, and plenty of solo practices are mediocre. Ownership is not destiny. It is just information, and right now it is information most patients never get. So get it.

A confident, patient-first practice will welcome every one of those questions, no matter who signs the paychecks. The ones that get defensive are telling you something too.